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Summary Between September 1981 and November 1984 the Danish Ovarian Cancer Group (DACOVA)
performed two randomised trials. One for adjuvant therapy in stages Ib, Ic and II and one for chemotherapy
treatment in stages III and IV. One hundred and twenty patients fulfilled criteria for the early stage protocol
but only 60% was randomised. Three hundred and sixty-one fulfilled criteria for the advanced stages protocol,
73% was randomised. In early stages 11% were excluded because of unavoidable reasons and 29% because of
avoidable reasons. In contrast, in advanced stages 21% were excluded because of unavoidable reasons and
only 6% because ofavoidable reasons. Allocation to the early stage protocol varied with stage, histologic type,
residual tumour, and the presence of ascites. These factors had no influence upon allocation to the advanced
stages protocol. The experience from this study is: only essential and simple questions should be examined in
multicentre trials. Patient accrual and the difference between randomisation groups are usually overestimated,
large scale trials are often required to get statistically significant differences, and the participation of
departments only randomising a small and selected part of their patients is questionable.
The scientific value of multicentre trials could be considered
from two different points of view. Many and well defined
exclusion and inclusion criteria will produce a homogenous
trial population and thereby reliable data. But too many
exclusion criteria will give results only valid for a subset of
patients and not suitable for generalisation in clinical prac-
tice. Comparison of results in randomised and non random-
ised patients will often show better results in randomised
patients. This is frequently claimed to be caused by better
medical care for randomised patients, but it may also be
caused by selection of patients with better prognosis for
randomised studies. Information about all patients fulfilling
randomisation criteria, included as well as excluded, should
therefore be available when the results from multicentre trials
are evaluated.
In 1981, 55 departments of gynaecology and surgery, 11
institutes of pathology and four centres of oncology estab-
lished the Danish Ovarian Cancer group, DACOVA. These
departments cover about 2/3 of the population in Denmark.
Since 1981 the group has performed several controlled ran-
domised trials comparing different treatment modalities. The
group has tried to register all patients in its catchment area.
This makes it possible to compare treatment and results for
randomised and non randomised patients and analyse escape
clauses in the trials.
From September 1981 to November 1984 the DACOVA
group performed two randomised studies for epithelial
ovarian cancer: one for adjuvant treatment of FIGO stages
Ib, Ic or II (Sell et al., 1990), and one for chemotherapy
treatment of FIGO stages III and IV (Bertelsen et al., 1987).
The aim of the following paper is to compare treatment
and survival in randomised and non randomised patients and
to analyse the reasons for excluding patients fulfilling pro-
tocol criteria.
Materials and methods
From September 1981 to November 1984, 716 patients with
epithelial ovarian cancer were registered in the DACOVA
register. The registration procedure was as follows: a record-
form should be filled in every time a new case of ovarian
cancer was diagnosed. An attempt was made to register all
patients with malignant epithelial ovarian cancer. The record
form was sent directly to the DACOVA register in patients
not fulfilling inclusion criteria for the randomised studies. In
patients fulfilling inclusion critera the record form was sent
to the regional oncologic centre, when the patient was refer-
red for postoperative treatment. After randomisation per-
formed locally, the record form was sent to the DACOVA
register. Only cases with histologic verification of diagnosis
were registered. Patients diagnosed at laparoscopy or post-
mortem examination were also included.
The patients registered by DACOVA represent a large
number of consecutively treated, unselected cases of ovarian
cancer. The number of patients registered in the DACOVA
register represented about 90% of the ovarian cancer patients
registered by the Danish Cancer Registry (Danish Cancer
Registry, 1984) in the catchment area in the involved period.
Patients registered by the Danish Cancer Registry had in
5% ofcases no histological verification ofdiagnosis. Further-
more, patients with abdominal tumours, possible ovarian
cancer, were registered as ovarian cancer in the Danish
Cancer Registry, but not in the DACOVA register. This
explains some of the differences between the number of
ovarian cancer registered in the DACOVA register and in the
Danish Cancer Registry.
Criteria for protocol allocation were:
(1) Below 70 years of age.
(2) Epithelial ovarian cancer with histological verification
of diagnosis.
(3) FIGO stages Tb, Ic, Ila, Ilb, lIc, III or IV.
Criteria for exclusion were:
(1) Medical contraindication for postoperative treatment.
(2) Concomitant malignant disease during the last 5 years,
except basocellular carcinoma of the skin or carcinoma
in situ of the uterine cervix.
(3) Refusal to participate in randomised trials.
Histological typing was performed according to WHO
'Common Epithelial Tumours' (Scully, 1977) and histological
grading according to the percentage of solid tissue (Mauch et
al., 1980): well-differentiated less than 10% (grade I); moder-
ately differentiated more than 10% and less than 50% (grade
II); poorly differentiated more than 50% (grade III). All
randomised patients had a routine pathological review by an
experienced gynaecologic pathologist. FIGO classification
was performed according to the 1976 classification.
Surgery
Received 2 January 1991; and in revised form 8 May 1991.
Surgery was performed according to protocol guidelines and
consisted of bilateral salpingo-oophorectomy, hysterectomy
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and omentectomy whenever possible. For patients with
advanced cancer an attempt was always made to do debulk-
ing surgery. At operation meticulous staging was made.
Postoperative treatment
Patients with FIGO stages Tb, Ic, IIa, lIb or Ilc allocated
to protocol were randomised to whole abdominal irradiation
or pelvic irradiation + cyclophosphamide. Whole abdominal
irradiation consisted of 22.50 Gy over 10 fractions to the
abdomen + pelvic boost 22.50 Gy over 10 fractions. Patients
treated with pelvic irradiation had 45.00 Gy over 20 fractions
to the true pelvis. The technique was a modification of the
technique used by Dembo and Bush (Dembo et al., 1979).
The dose of cyclophosphamide was 200mgm2 for 5 days
every 4 weeks for 12 cycles. One year after randomisation
patients without clinical evidence of disease had a second-
look laparotomy.
Patients with stage III or IV allocated to protocol were
randomised to cyclophosphamide and cisplatinum (CP)
or cyclophosphamide, cisplatinum and doxorubicin (CAP).
The doses were: cyclophosphamide 500 mg m2; cisplatinum
60 mg m-2 and doxorubicin 40 mg m-2. Chemotherapy was
given every 4 weeks and repeated 12 times. Patients in
clinical response had a second-look laparotomy 1 month
after the last cycle of chemotherapy.
Both randomised studies showed no survival differences
between the regimens (Sell et al., 1990; Bertelsen et al., 1987).
Non randomised patients in early stages were mainly treat-
ed with a combination of pelvic irradiation and cyclophos-
phamide, or with cisplatinum containing chemotherapy, if
they had postoperative therapy at all. Advanced stages were
treated with different chemotherapy regimens.
Follow-up
Follow-up information was collected prospectively for all
randomised patients. For non randomised patients informa-
tion about primary surgery and pathology was collected
prospectively, and information about treatment, recurrence,
and survival was obtained retrospectively. Cut-off day was
July 1990. Observation time is 68-106 months. No patient
was lost to follow-up.
Statistical method
Survival was estimated by the Kaplan Meier method and
tested for differences by the Mantel Haenzel test. Survival
was calculated from the date of operation to the date of
death or 1 July 1990 - whichever occurred first.
Exclusion reasons
The reasons for exclusions were divided in unavoidable and
avoidable reasons. Exclusion criteria foreseen in the protocol,
postoperative death, diagnosis at autopsy, psychiatric disease,
and doubt about the histologic diagnosis at start of post-
operative treatment were considered as unavoidable exclusion
reasons. Exclusion of patients because of medical condition
not allowing chemo-radiotherapy is of course a subjective
decision. But the majority of patients excluded by medical
contraindication had very advanced disease.
DATA calculation
It was estimated that patient accrual for the adjuvant proto-
col would be 50 patients per year and for the chemotherapy
protocol 100 patients per year. The number required for a
statistically significant difference of 15% was calculated to
300 patients in both trials.
Results
Between September 1981 and November 1984, 716 patients
with epithelial ovarian cancer were registered (Table I).
Twenty-three per cent was classified as stage I, 11% as stage
II, 48% as stage III, and 15% as stage IV. The FIGO
distribution showed minor statistically insignificant differ-
ences between the various centres. One hundred and four
patients were classified as stage Ia, 131 of the remaining
patients were older than 70 years. After exclusion of these
235 patients a total of 481 theoretically fulfilled protocol
criterial (Table II). Three hundred and thirty-seven or 70%
of the 481 eligible patients were included in the randomised
trials. The total number of eligible patients and the number
of randomised patients varied a little from year to year. The
first year 68% was randomised, the second 74%, and the
third 70%.
In early stages 120 patients fulfilled inclusion criteria
(Table II), but only 60% (72) were randomised. In advanced
stages 361 patients fulfilled inclusion criteria, 73% (265) were
randomised. The difference between randomisation percen-
tage in early and advanced stages were statistically significant
(X2 = 7.718, d.f. = 1, P=0.0055).
Treatment
Five patients had no laparotomy: four non randomised
patients, one diagnosed at laparoscopy and three at post-
mortem examination, and one randomised patients with
vaginal metastases. Another 14 patients with advanced
tumour had no postoperative treatment and died within 1
month after explorative laparotomy. After exclusion of these
19 patients 462 remained for analysis of postoperative treat-
ment. Stages I and II still comprised 120 patients, but stages
III and IV now comprised only 342 patients. Patients in stage
Tb, Ic, and II allocated to protocol had in 49% whole
abdominal irradiation and in 51% pelvic irradiation plus
cyclophosphamide (Table ITT). The preferred treatment for
non randomised patients in stage I and II was pelvic irradia-
tion plus cyclophosphamide, which was given in 31%, and
cisplatinum containing chemotherapy which was given in
27%; 23% had no postoperative treatment. Advanced staged
allocated to protocol had in 51% CAP and in 49% CP. Non
randomised patients were in 47% treated with cisplatinum
containing poly-chemotherapy. Single drug alkylating agent
was given in 22%, 24% had no postoperative treatment at
all.
Survival
Survival for all patients showed that randomised patients had
a better survival than non randomised patients (Figure 1).
The difference was statistically significant (P = 0.0005). For
stages Tb, Ic or II there were no difference between survival
in randomised and non randomised patients (P = 0.45) but
stages III and IV randomised patients had a statistically
significant better survival than non randomised patients
(P = 0.0002). The survival superiority in randomised patients
disappeared when groups with similar stages and treatments
were compared. In stages III and IV there was no difference
in survival when only patients treated with combination
chemotherapy were compared (Figure 2) (P = 0.98).
Exclusion reasons
In stages Tb, Ic, and IT 60% were randomised, 11% were
excluded because ofunavoidable reasons and 29% because of
avoidable reasons (Table TI). In contrast 73% were random-
ised in stages III and IV. Twenty-one per cent was excluded
because of unavoidable reasons and only 6% because of
avoidable reasons. The difference between early stages and
advanced stages in the percentage of avoidable excluded
patients was statistically significant (X2 = 35.080, d.f. = 1,
P = 0.0000). Medical contraindication and refusal were un-
avoidable exclusion reasons for seven out of 13 patients in1174 K. BERTELSEN
Table I FIGO classification distributed according to oncologic centre
Centre
A B C D Total
FIGO stage n (%) n (%) n (%) n (%) n (%)
Iai 3 (4) 27 (9) 21 (10) 17 (12) 68 (10)
laii 5 (7) 13 (5) 10 (5) 8 (6) 36 (5)
Ibi 2 (3) 3 (1) 5 (2) 0 (0) 10 (1)
Ibii 0 (0) 1 (0) 7 (3) 0 (0) 8 (1)
Ic 6 (8) 15 (5) 13 (6) 12 (9) 46 (6)
Ila 1 (1) 7 (2) 5 (2) 2 (1) 15 (2)
Ilb 3 (4) 15 (5) 10 (5) 6 (4) 34 (5)
IIc 2 (3) 16 (6) 9 (4) 2 (1) 29 (4)
III 47 (65) 133 (46) 90 (42) 76 (55) 346 (48)
IV 3 (4) 55 (19) 37 (17) 14 (10) 109 (15)
No laparotomy 0 (0) 5 (2) 8 (4) 2 (1) 15 (2)
Total 72 290 215 139 716
Table II Reasons for exclusions distributed by protocol
Randomised
Non randomised
Reasons for exclusions
Unavoidable
Other cancer
Previous irradiation
Medical contraindication
Dead postoperatively
Diagnosed at autopsy
Uncertain histology
Psychiatric disease
Refusal
Avoidable
Insufficient staging
Wrong FIGO stage
Misunderstanding of criteria
Chemotherapy preoperatively
Delayed trial start
Physicians decision
Various
FIGO stages
Ib,Ic,II III, IV
72 60% 265 73%
48 40% 96 27%
13 11%
0
2
4
0
0
2
2
3
35 29%
11
17
3
1
0
2
1
75 21%
14
2
39
3
3
3
1
10
21 6%
2
0
10
4
2
1
2
80 Total
337 70%
144 30%
88 18%
14
4
43
3
3
S
3
13
56 12%
13
17
13
S
2
3
3
early stages. The most frequent avoidable exclusion reason
for early stages was wrong FIGO classification, which occur-
red among 17 out of 35 cases. Fifteen patients with unilateral
tumour and ascites without tumour cells were classified as
stage Ia after surgery. The correct classification was Ic. Two
cases in stage Ilb were primarily classified as stage III and
allocated to the protocol for stages III and IV. Eleven
patients were excluded because of insufficient staging. In
advanced stages 39 out of 75 unavoidable excluded patients,
were not randomised because ofmedical condition not allow-
ing chemotherapy. WHO performance score was in several
patients 3 or 4, 11 died within 1 month after diagnosis. The
most frequent avoidable exclusion reasons for stages III and
IV was misunderstanding of protocol inclusion and exclusion
criteria. One centre had, in contradiction to protocol guide-
lines, the opinion, that patients only explorative laparotomis-
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Figure 1 Survival in 481 patients fulfilling randomisation criteria
distributed according to protocol.
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Figure 2 Survival in 281 stages III and IV patients treated with
cisplatinum polychemotherapy, distributed in randomised (264),
and non randomised patients (37).
ed should not be randomised. Eight patients were excluded
because of this reason.
The percentage of randomised patients showed a statisti-
Table III Distribution of treatment in relation to protocol and randomisation
Ib, Ic and II III and IV
Randomised Randomised
Yes No Yes No
Treatment n (%) n (%) n (%) n (%)
Whole Abd.RT 35 (49) 1 (2) 0 (0) 0 (0)
Pelvic RT 0 (0) 2 (4) 0 (0) 1 (1)
Pelvic RT + Cyclo 37 (51) 15 (31) 0 (0) 4 (5)
Alkylating single drug 0 (0) 6 (13) 0 (0) 17 (22)
Cisplatin polychemotherapy 0 (0) 13 (27) 264 (100) 37 (47)
No treatment 0 (0) 11 (23) 0 (0) 19 (24)
72 48 264* 78
*19 patients excluded, five without laparotomy and 14 died within a month after
exploratory laparotomy.
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cally insignificant difference between centres A and the
remaining centres. Centre A included only 43% in the proto-
col for early stages and 58% in the protocol for advanced
stages vs 62% and 75% for the remaining centres (Table IV)
(P values 0.38 and 0.10 respectively). However, at centre A
statistically significant more patients were excluded because
of avoidable exclusion reasons than at the other centres, 31%
vs 9% (Table V) (X2 = 23.274, d.f. = 1, P = 0.0000).
The relationship between randomisation and characteristics
of patients eligible for the early stage protocol is shown in
Table VI. Patients in FIGO stage Ic, with mucinous carcin-
oma, residual tumour larger than 1 cm in diameter, or ascites
had a lower frequency of randomisation than the total group.
Stage Ic was, as mentioned above, not randomised because
of misinterpretation of the FIGO classification. The central
DACOVA register changed the classification from Ta to Ic
for 15 patients with ascites exceeding 100 ml. Patients with
mucinous carcinoma or with residual tumour larger than
Table IV Protocol allocation, distribution by centre and protocol
FIGO stages
Ib, Ic and I! III and IV
Randomised Randomised
Yes No Yes No
n (%) n n (%) n
Centres
A 6 (43) 8 23 (58) 17
B 26 (56) 20 115 (77) 34
C 27 (68) 13 76 (75) 26
D 13 (65) 7 51 (73) 19
Total 72 48 265 96
X2 = 3.092, d.f. = 3, P= 0.38; x2 = 6.346, d.f. = 3, P=0.10.
Table V Protocol allocation distributed bycentreand byunavoidable/
avoidable exclusion reasons
Randomised Non randomised
Yes No Unavoidably Avoidably
n (%) n (%) n (%) n (%)
A 29 (54) 25 (46) 8 (15) 17 (31)
B 141 (72) 54 (28) 37 (20) 17 (8)
C 103 (73) 39 (27) 25 (17) 14 (10)
D 64 (71) 26 (29) 18 (20) 8 (9)
337 144 88 56
Table VI Randomisation in relation to charactistics of 120 FIGO
stage Ib, Ic, and II patients
Randomised
Yes No
n (%) n
Number of patients 72 (60) 48
FIGO stage
lb 13 (87) 2
Ic 19 (48) 21
Ila 10 (71) 4
IIb 15 (58) 11
IIc 15 (60) 10
Histological type
Serous carcinoma 29 (69) 13
Mucinous carcinoma 6 (38) 10
Endometrioid carcinoma 26 (63) 15
Clear cell carcinoma 4 (67) 2
Undifferentiated carcinoma 6 (67) 3
Mixed carcinoma 1 (17) 5
Residual tumour (Stage IIb and lIc)
None 17 (77) 5
<1 cm 7 (70) 3
>1cm 6 (35) 11
Unknown 0 (0) 2
Ascites 15 (37) 26
No ascites 57 (72) 22
Tumour cells in ascites/washings 20 (77) 6
No tumour cells 23 (49) 24
Not examined 29 (62) 18
1 cm in diameter or ascites were excluded because the
physician in charge thought that the protocol treatment
would be inappropriate. Only 35% of the eligible patients
with residual tumour larger than 1 cm was randomised. The
relationship between randomisation and characteristics of
patients eligible for the advanced stage protocol is shown in
Table VII. FIGO stage, histological type, size of residual
tumour and the presence of ascites had no influence on
protocol allocation.
Discussion
Four hundred and eighty-one patients were theoretically
eligible for randomisation in these multicentre trials for
epithelial ovarian cancer, but only 70% were randomised.
The stage distribution and thereby the number of patients
available for randomisation depends upon staging procedure.
Careful staging reduces the number of patients in early
stages. One centre had in fact a lower frequency of stage Iai.
The main reason for this is probably incomplete registration
of non randomised patients and not an inferior staging pro-
cedure. The study showed statistically significant differences
in acceptance and exclusion reasons of the two protocols.
For early stages, Tb, Ic or TI, only 60% were randomised,
11% were excluded because of unavoidable reasons and as
much as 29% because of avoidable reasons. Twenty-eight
among 48 excluded patients were not randomised because of
wrong FIGO classification or insufficient staging. In stages
III or IV 73% of the eligible patients were randomised, 21%
were excluded because of unavoidable and only 6% because
of avoidable reasons. Medical condition not allowing chemo-
therapy was the most frequent unavoidable exclusion reason.
Eighty-nine per cent of early stages and 79% of advanced
stages could have been randomised if all patients excluded by
avoidable reasons, had been included. Allocation to the early
stages trial was not satisfactory. The number of randomised
patients included only two thirds of the available patients.
For advanced stages almost all available patients were ran-
domised. The difference is probably explained by a difference
in the trial question and not by a difference in administration
and monitoring of the trials. The chemotherapy protocol was
a simple question and all the investigators felt a need for new
treatment and better results. The question of protocol for the
early stages was more complicated. The treatment was rather
toxic, considered adjuvant, and many investigators doubted
the efficacy of whole abdominal irradiation.
Table VII Randomisation in relation to characteristics of342* FIGO
stage III and IV patients
Randomised
Yes No
n (%) n
Number of patients 264* (77) 78
FIGO stage
III 207 (78) 59
IV 57 (75) 19
Histologic type
Serous carcinoma 154 (80) 38
Mucinous carcinoma 18 (64) 10
Endometrioid carcinoma 43 (77) 13
Clear cell carcinoma 7 (88) 1
Undifferentiated carcinoma 35 (71) 14
Mixed carcinoma 7 (78) 2
Residual tumour
None 24 (75) 8
<1 cm 43 (88) 6
>1 cm 187 (75) 61
Unknown 10 (77) 3
Ascites 183 (77) 56
No ascites 81 (79) 22
Tumour cell in ascites/washings 147 (81) 34
No tumour cells 54 (68) 25
Not examined 63 (77) 19
*19 excluded, five without laparotomy and 14 dead within a month
after laparotomy.1176 K. BERTELSEN
Furthermore the present study suggested that allocation to
the early stage protocol varied with centre, FIGO stage,
histological type, and residual tumour. Stage Ic was excluded
because of a general misclassification of patients with ascites
without tumour cells. The remaining patients were excluded
for various subjective reasons. The randomised population
was then a selected subset of the total patient population. It
may be that the results are true only in this subset and for
not all stages Ib, Ic and II. Allocation to the protocol for
advanced stages varied with centre, but not with other fac-
tors; the main exclusion reason was medical condition not
allowing chemotherapy. Centre A excluded a statistically
significant greater number of patients because of avoidable
reasons than the other centres.
The percentage ofrandomised patients in the present study
was similar to the percentage of eligible patients randomised
in other Danish multicentre trials. The Danish colo-rectal
multicentre study group included 57% of eligible patients in
a randomised study testing the efficacy of postoperative irra-
diation in colo-rectal cancer Dukes stage B and C (Kronborg
et al., 1988). The majority (92%), was excluded because of
reasons agreed upon beforehand. However, this trial had a
very long list of protocol exclusion criteria. In the Danish
Breast Cancer Cooperative Group 20-30% of patients below
70 years of age were not included in the various protocols
(West Andersen et al., 1988).
Survival of randomised patients was better than survival of
non randomised patients. This is probably caused by selec-
tion of patients with better prognosis for randomised studies.
Non randomised patients were patients with bad prognosis.
The difference in survival disappeared when groups with
similar prognostic characteristics and similar treatments were
compared. Thus, advanced stages treated with cisplatinum
containing chemotherapy showed no survival difference
between randomised and non randomised patients.
For early stages the number of randomised patients was
below the estimated number, 20 vs 50 per year. For advanced
stages the estimate was correct. Both trials were unable to
show a statistically significant survival difference between the
randomisatioiL groups. The protocol for early stages stopped
in November 1988. A study testing the effect of adjuvant
treatment in early ovarian cancer will require participation of
a large number or departments because of the small number
of patients in stages I and II. The chemotherapy protocol
stopped in November 1984 after inclusion of 265 patients.
Recently this trial has been analysed together with four other
trials randomising between CAP and CP (Ovarian Cancer
Meta- Analysis Group, 1991). The five trials included 1,194
patients. A statistically significant difference for 5 year sur-
vival in favour of the CAP regimen was observed (P = 0.02).
The observed difference was 6% and not 15% as estimated.
Considering the poor survival ofadvanced ovarian cancer the
6% improvement is ofclinical interest. A realistic estimate of
the expected difference at the beginning of the trial would
have demonstrated that a large scale study with participation
ofdepartments outside Denmark was necessary. A large scale
trial had required a different study design recording only very
few data.
The present study showed that the patient allocation to a
multicentre trial is influenced by many factors. In setting up
randomised trials the following should be considered.
(1) Only essential and simple questions should be exam-
ined in multicentre trials.
(2) Realistic data estimates should be performed. Patient
accrual and the difference between treatments groups
are usually overestimated. A statistically significant
difference will very often require inclusion of a large
number of patients.
(3) Participation of departments randomising a small and
selected part of their patients is questionable. Results
based on data from these selected patients may be of
no use in clinical pratice.
We are grateful to the DACOVA group and the Danish Cancer
Society which supported the study with grants.
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